BACKGROUND/AIMS: Recent studies suggest that antecedent disease could impact the pathophysiology of the motoneuron disease Amyotrophic Lateral Sclerosis (ALS). We performed a case-control study to examine the prevalence of 11 antecedent diseases in ALS. METHODS: Prevalence of antecedent disease in a 1,288 patient ALS population (Emory University ALS Clinic, Atlanta, Ga., USA) is compared to an age, gender, and geography-matched 7,561 subject control population using a statistical odds ratio (OR) with 95% confidence interval. RESULTS: Association of ALS with odds of arthritis (OR = 0.14); non-ALS neurological disease (OR = 0.14); liver disease (OR = 0.19); chronic obstructive pulmonary disorder or COPD (OR = 0.23); kidney disease (OR = 0.32); adult asthma (OR = 0.39); diabetes (OR = 0.47); hypertension (OR = 0.56); obesity (OR = 0.6); hyperlipidemia or hypercholesterolemia (OR = 0.62); and thyroid disease (OR = 0.78). CONCLUSIONS: The prevalence of antecedent disease was overall less in the ALS population. We present two potential lines of inquiry to explain these results: (1) 'Other disease as ALS protection'--antecedent diseases infer biochemical neuroprotection to ALS; (2) 'ALS as other disease protection'--the underpinnings of ALS could infer protection to other diseases, possibly via the mechanism hypervigilant regulation or 'too-high' regulatory feedback gains.
BACKGROUND/AIMS: Recent studies suggest that antecedent disease could impact the pathophysiology of the motoneuron disease Amyotrophic Lateral Sclerosis (ALS). We performed a case-control study to examine the prevalence of 11 antecedent diseases in ALS. METHODS: Prevalence of antecedent disease in a 1,288 patientALS population (Emory University ALS Clinic, Atlanta, Ga., USA) is compared to an age, gender, and geography-matched 7,561 subject control population using a statistical odds ratio (OR) with 95% confidence interval. RESULTS: Association of ALS with odds of arthritis (OR = 0.14); non-ALS neurological disease (OR = 0.14); liver disease (OR = 0.19); chronic obstructive pulmonary disorder or COPD (OR = 0.23); kidney disease (OR = 0.32); adult asthma (OR = 0.39); diabetes (OR = 0.47); hypertension (OR = 0.56); obesity (OR = 0.6); hyperlipidemia or hypercholesterolemia (OR = 0.62); and thyroid disease (OR = 0.78). CONCLUSIONS: The prevalence of antecedent disease was overall less in the ALS population. We present two potential lines of inquiry to explain these results: (1) 'Other disease as ALS protection'--antecedent diseases infer biochemical neuroprotection to ALS; (2) 'ALS as other disease protection'--the underpinnings of ALS could infer protection to other diseases, possibly via the mechanism hypervigilant regulation or 'too-high' regulatory feedback gains.
Authors: Marek Cyrklaff; Cecilia P Sanchez; Nicole Kilian; Cyrille Bisseye; Jacques Simpore; Friedrich Frischknecht; Michael Lanzer Journal: Science Date: 2011-11-10 Impact factor: 47.728
Authors: Perry T C van Doormaal; Alessandro Gallo; Wouter van Rheenen; Jan H Veldink; Michael A van Es; Leonard H van den Berg Journal: J Neurol Neurosurg Psychiatry Date: 2013-04-17 Impact factor: 10.154
Authors: N A Sutedja; Y T van der Schouw; K Fischer; E M Sizoo; M H B Huisman; J H Veldink; L H Van den Berg Journal: J Neurol Neurosurg Psychiatry Date: 2011-04-06 Impact factor: 10.154
Authors: L Dupuis; P Corcia; A Fergani; J-L Gonzalez De Aguilar; D Bonnefont-Rousselot; R Bittar; D Seilhean; J-J Hauw; L Lacomblez; J-P Loeffler; V Meininger Journal: Neurology Date: 2008-01-16 Impact factor: 9.910
Authors: C Bouteloup; J-C Desport; P Clavelou; N Guy; H Derumeaux-Burel; A Ferrier; P Couratier Journal: J Neurol Date: 2009-03-22 Impact factor: 4.849
Authors: Martin R Turner; Raph Goldacre; Sreeram Ramagopalan; Kevin Talbot; Michael J Goldacre Journal: Neurology Date: 2013-08-14 Impact factor: 9.910
Authors: Albert A Taylor; Christina Fournier; Meraida Polak; Liuxia Wang; Neta Zach; Mike Keymer; Jonathan D Glass; David L Ennist Journal: Ann Clin Transl Neurol Date: 2016-09-07 Impact factor: 4.511